Other common mutations aberrantly activate signaling molecules, involving classical oncogenes as for example Ras, or, more AML-specific oncogenic effectors like the receptor tyrosine kinase fms like tyrosine kinase 3 (FLT3), that is mutated in about 30% of the cases. The gene discussed is FLT3; the disease is acute myeloid leukemia.